Knowles Corp: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Oct 28, 2025 and accepted by EDGAR at Oct 28, 2025, 16:02 ET.
Management's discussion and analysis
As filed, 57,971 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q.
Overview
We are a leading manufacturer of specialty electronic components. We design parts that perform unique and critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, we enable businesses to succeed in the most demanding applications across medtech, defense, industrial, and electrification markets. Our high performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, and balanced armature speakers, enhance the performance of our customers products to change, improve, and save lives. Our focus on the customer, combined with unique technology, proprietary manufacturing techniques, and global operational expertise, enables us to deliver innovative solutions across multiple applications. References to "Knowles," the "Company," "we," "our," or "us" refer to Knowles Corporation and its consolidated subsidiaries, unless the context otherwise requires.
We sell our products directly to original equipment manufacturers ("OEMs") and to their contract manufacturers and suppliers and through distributors worldwide.
Recent Developments
On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus an additional country-specific tariff for select trading partners, on all U.S. imports. These actions, and retaliatory tariffs imposed by foreign jurisdictions, have resulted in market volatility and uncertainty regarding the ultimate effect of the tariffs on global economic conditions. We do not anticipate that these factors will have a material impact on our operations; however, we continue to monitor changes in international trade relations and trade policy, including those related to tariffs, which could adversely impact our results. We are optimizing operations and leveraging existing programs and strategies to reduce the impact from tariffs. Additionally, we are taking measures to control costs and implementing pricing actions designed to mitigate the risk these policies may have on our revenues and operations.
On December 27, 2024, the Company consummated the sale and assignment of certain assets and liabilities of the Company’s Consumer MEMS Microphones ("CMM") segment to Syntiant Corp. ("Syntiant") for approximately $150.0 million in total consideration, consisting of $70.0 million cash ($58.0 million in net cash received) as adjusted for agreed deductions for indebtedness, and working capital and $80.0 million in Syntiant Series D-2 preferred stock (with a fair value of $77.2 million), par value $0.0001. The Company provided $6.4 million in financing, which was utilized to fund Syntiant's requirement to have $40.0 million of cash on its balance sheet at closing. The Company will also share in certain separation costs pursuant to a credit, which Syntiant may apply to specified separation costs post-closing. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements under Part I, Item 1, "Financial Statements."
We have reclassified the results of operations and financial position of CMM to discontinued operations for all periods presented. Unless otherwise noted, our results of operations discussed below relate to continuing operations and will be impacted by the CMM divestiture.
This divestiture supports Knowles' continued transformation into an industrial technology company, consisting of its Precision Devices ("PD") and MedTech & Specialty Audio ("MSA") segments, primarily serving the defense, medtech, industrial, and electrification markets. We have incurred some amount of dis-synergies following the sale of CMM due to the reduced size of our company and, as a result, we have undertaken actions to help ensure that our cost structure is appropriate to support our remaining businesses.
As inventory levels in the industrial markets have recently begun to normalize, our Precision Devices segment has experienced increased bookings for the past four quarters. In addition, with bookings increasing we have seen backlog across our capacitor products increase for the past four quarters.
Non-GAAP Financial Measures
In addition to the GAAP financial measures included in this item, we have presented certain non-GAAP financial measures. We use non-GAAP measures as supplements to our GAAP results of operations in evaluating certain aspects of our business, and our executive management team and Board of Directors focus on non-GAAP items as key measures of our performance for business planning purposes. These measures assist us in comparing our performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in our opinion, do not reflect our core operating performance. We believe that our presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that we use internally for purposes of assessing our core operating performance. The Company does not consider these non-GAAP financial measures to be a substitute for the information provided by GAAP financial results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the reconciliation included herein.
Results of Operations for the Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024
(in millions, except per share amounts)
| Three Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| Revenues | $152.9 | $142.5 |
| Gross profit | $69.9 | $62.9 |
| Non-GAAP gross profit | $70.7 | $64.8 |
| Earnings from continuing operations before interest and income taxes | $24.6 | $16.1 |
| Adjusted earnings from continuing operations before interest and income taxes | $34.5 | $30.0 |
| Provision for income taxes | $4.3 | $3.0 |
| Non-GAAP provision for income taxes | $3.3 | $1.9 |
| Net earnings from continuing operations | $18.0 | $9.2 |
| Non-GAAP net earnings from continuing operations | $28.9 | $24.2 |
| Earnings per share from continuing operations - diluted | $0.21 | $0.10 |
| Non-GAAP diluted earnings per share | $0.33 | $0.27 |
Revenues
Revenues for the third quarter of 2025 were $152.9 million, compared with $142.5 million for the third quarter of 2024, an increase of $10.4 million or 7.3%. PD revenues increased $9.4 million due to higher demand in the defense, electrification, medtech, and industrial markets, as well as higher average pricing. MSA revenues increased $1.0 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and higher shipping volumes into the specialty audio market, partially offset by lower shipping volumes into the hearing health market.
Cost of Goods Sold
Cost of goods sold ("COGS") for the third quarter of 2025 was $82.8 million, compared with $79.5 million for the third quarter of 2024, an increase of $3.3 million or 4.2%. This increase was primarily due to higher shipping volumes, unfavorable product mix, and lower than expected yields in our CD business as we ramp up our specialty film product line, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, favorable inventory reserve adjustments, a reduction of CD related production transfer costs, and lower precious metal costs.
Restructuring Charges
During the third quarter of 2025, we recorded restructuring charges of $0.3 million related primarily to headcount reductions across the Company to rightsize expenses subsequent to the sale of CMM. During the third quarter of 2024, we recorded restructuring charges of $0.2 million for headcount reductions and costs to transfer certain capacitors manufacturing to existing facilities to further optimize operations. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.
Gross Profit and Non-GAAP Gross Profit
Gross profit for the third quarter of 2025 was $69.9 million, compared with $62.9 million for the third quarter of 2024, an increase of $7.0 million or 11.1%. Gross profit margin (gross profit as a percentage of revenues) for the third quarter of 2025 was 45.7%, compared with 44.1% for the third quarter of 2024. The increases in gross profit and gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.
Non-GAAP gross profit for the third quarter of 2025 was $70.7 million, compared with $64.8 million for the third quarter of 2024, an increase of $5.9 million or 9.1%. Non-GAAP gross profit margin (non-GAAP gross profit as a percentage of revenues) for the third quarter of 2025 was 46.2% compared with 45.5% for the third quarter of 2024. The increases in non-GAAP gross profit and non-GAAP gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.
Research and Development Expenses
Research and development expenses for the third quarter of 2025 were $10.0 million, compared with $10.2 million for the third quarter of 2024, a decrease of $0.2 million or 2.0%. Research and development expenses as a percentage of revenues for the third quarter of 2025 and 2024 were 6.5% and 7.2%, respectively. The decreases in expenses were primarily driven by the timing of some development activities. The decrease in expenses as a percentage of revenues was driven by higher revenues.
Selling and Administrative Expenses
Selling and administrative expenses for the third quarter of 2025 were $34.0 million, compared with $33.9 million for the third quarter of 2024, an increase of $0.1 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the third quarter of 2025 and 2024 were 22.2% and 23.8%, respectively. The increase in expenses was primarily driven by higher incentive compensation, partially offset by a reduction of CD related acquisition costs and the benefits of restructuring actions. The decrease in expenses as a percentage of revenues was driven by higher revenues.
Interest Expense, net
Interest expense for the third quarter of 2025 was $2.3 million, compared with $3.9 million for the third quarter of 2024, a decrease of $1.6 million. The decrease is due to a lower outstanding revolving credit facility balance during the third quarter of 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 9. Borrowings to our Consolidated Financial Statements.
Other Expense, net
Other expense for the third quarter of 2025 was $1.2 million, compared with expense of $2.6 million for the third quarter of 2024, a change of $1.4 million. Expense in both 2025 and 2024 is primarily due to unfavorable foreign currency exchange rate changes.
Provision for Income Taxes and Non-GAAP Provision for Income Taxes
Effective tax rate ("ETR") for the third quarter of 2025 and 2024 was 19.3% and 24.6%, respectively. The ETR for the third quarter of 2025 and 2024 includes discrete items totaling $0.2 million of tax expense and $0.7 million of tax benefit, respectively. The discrete items impacting the tax provision for 2025 and 2024 are primarily attributable to stock-based compensation and the deferred tax impact of a tax rate change. Absent the discrete items, the ETR for the third quarter of 2025 and 2024 was 18.4% and 30.3%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provisions for the third quarter of 2025 and 2024, respectively. The change in the ETR was due to the mix of earnings and losses by taxing jurisdictions and net discrete items.
Non-GAAP ETR for the third quarter of 2025 and 2024 was 10.2% and 7.3%, respectively. The non-GAAP ETR includes discrete items totaling $0.1 million of tax expense and $0.9 million of tax benefit for the three months ended September 30, 2025 and 2024, respectively. Absent the discrete items, the non-GAAP ETR for the third quarter of 2025 and 2024 was 9.9% and 10.7%, respectively. The change in the non-GAAP ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.
On July 4, 2025, the One Big Beautiful Bill Act was signed into U.S. federal law. Based on our analysis of the law, we do not anticipate the One Big Beautiful Bill Act having a material impact on the financial statements of Knowles in 2025 or subsequent years.
Earnings from Continuing Operations
Earnings from continuing operations for the third quarter of 2025 was $18.0 million, compared with $9.2 million for the third quarter of 2024, an improvement of $8.8 million. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher income tax expense.
Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes
Earnings from continuing operations before interest and income taxes ("EBIT") for the third quarter of 2025 was $24.6 million, compared with $16.1 million for the third quarter of 2024, an increase of $8.5 million. EBIT margin (EBIT as a percentage of revenues) for the third quarter of 2025 was 16.1%, compared with 11.3% for the third quarter of 2024. The increase in EBIT and EBIT margin was primarily due to higher gross profit.
Adjusted earnings before interest and income taxes ("Adjusted EBIT") from continuing operations for the third quarter of 2025 was $34.5 million, compared with $30.0 million for the third quarter of 2024, an increase of $4.5 million. Adjusted EBIT margin (Adjusted EBIT from continuing operations as a percentage of revenues) for the third quarter of 2025 was 22.6%, compared with 21.1% for the third quarter of 2024. The increase in Adjusted EBIT and Adjusted EBIT margin was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses.
Loss from Discontinued Operations, net
We recorded a loss of $0.6 million for the third quarter of 2025, primarily driven by a change in tax expense. We recorded a loss of $8.7 million for the third quarter of 2024, primarily driven by our goodwill impairment and loss on disposal of business related to the divestiture of CMM, partially offset by favorable income tax changes. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.
Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations
Diluted earnings per share from continuing operations was $0.21 for the third quarter of 2025, compared with $0.10 for the third quarter of 2024, an improvement of $0.11. As described above, the improvement is primarily due to higher gross profit, lower interest expense and reduced share count, partially offset by higher income tax expense.
Non-GAAP diluted earnings per share from continuing operations was $0.33 for the third quarter of 2025, compared with $0.27 for the third quarter of 2024, an improvement of $0.06. As described above, the improvement is primarily due to higher non-GAAP gross profit, lower interest expense, and reduced share count, partially offset by higher non-GAAP operating expenses and higher non-GAAP income tax expense.
Results of Operations for the Nine Months Ended September 30, 2025 compared with the Nine Months Ended September 30, 2024
(in millions, except per share amounts)
| Nine Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| Revenues | $431.0 | $411.0 |
| Gross profit | $183.8 | $173.9 |
| Non-GAAP gross profit | $190.2 | $182.5 |
| Earnings from continuing operations before interest and income taxes | $41.9 | $33.9 |
| Adjusted earnings from continuing operations before interest and income taxes | $83.9 | $78.5 |
| Provision for income taxes | $9.0 | $8.0 |
| Non-GAAP provision for income taxes | $10.1 | $6.0 |
| Net earnings from continuing operations | $25.4 | $13.0 |
| Non-GAAP net earnings from continuing operations | $66.3 | $59.6 |
| Earnings per share from continuing operations - diluted | $0.29 | $0.14 |
| Non-GAAP diluted earnings per share | $0.75 | $0.65 |
Revenues
Revenues for the nine months ended September 30, 2025 were $431.0 million, compared with $411.0 million for the nine months ended September 30, 2024, an increase of $20.0 million or 4.9%. PD revenues increased $12.0 million due to higher demand from the medtech, electrification, and defense markets, as well as higher average pricing, partially offset by lower demand from the industrial market. MSA revenues increased $8.0 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio market, partially offset by lower average pricing on mature products and lower shipping volumes into the hearing health market.
Cost of Goods Sold
COGS for the nine months ended September 30, 2025 was $242.9 million, compared with $235.7 million for the nine months ended September 30, 2024, an increase of $7.2 million or 3.1%. This increase was primarily due to higher shipping volumes, unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, a reduction of CD related acquisition and production transfer costs, and lower precious metal costs.
Impairment Charges
During the nine months ended September 30, 2025, we recorded an impairment charge of $3.6 million to write down the carrying value of certain machinery and equipment to fair value. For additional information, refer to Note 1. Basis of Presentation to our Consolidated Financial Statements.
Restructuring Charges
During the nine months ended September 30, 2025, we recorded restructuring charges of $0.7 million within Gross profit and $2.5 million within Operating expenses primarily related to headcount reductions across the Company to rightsize operating expenses subsequent to the sale of CMM. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.
During the nine months ended September 30, 2024, we recorded restructuring charges of $1.8 million related to headcount reductions and $1.1 million for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations within our PD segment. These actions resulted in restructuring charges of $1.4 million within Gross profit and $1.5 million within Operating expenses. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.
Gross Profit and Non-GAAP Gross Profit
Gross profit for the nine months ended September 30, 2025 was $183.8 million, compared with $173.9 million for the nine months ended September 30, 2024, an increase of $9.9 million or 5.7%. Gross profit margin for the nine months ended September 30, 2025 was 42.6%, compared with 42.3% for the nine months ended September 30, 2024. The increases in gross profit and gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, a reduction of CD related acquisition and production transfer costs, lower precious metal costs and restructuring charges, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on mature products in the MSA business, impairment charges in 2025, and unfavorable inventory reserve adjustments.
Non-GAAP gross profit for the nine months ended September 30, 2025 was $190.2 million, compared with $182.5 million for the nine months ended September 30, 2024, an increase of $7.7 million or 4.2%. Non-GAAP gross profit margin for the nine months ended September 30, 2025 was 44.1%, compared with 44.4% for the nine months ended September 30, 2024. The increase in non-GAAP gross profit was primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, and lower precious metal costs, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on mature products in the MSA business, and unfavorable inventory reserve adjustments. The decrease in non-GAAP gross profit margin is primarily due to unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on our mature products in the MSA business, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, and lower precious metals costs.
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2025 were $29.7 million, compared with $29.2 million for the nine months ended September 30, 2024, an increase of $0.5 million or 1.7%. Research and development expenses as a percentage of revenues for the nine months ended September 30, 2025 and 2024 were 6.9% and 7.1%, respectively. The increase in expenses was primarily driven by increased development activities as we continue to invest in our businesses. The decrease in expenses as a percentage of revenues was driven by higher revenues.
Selling and Administrative Expenses
Selling and administrative expenses for the nine months ended September 30, 2025 were $107.1 million, compared with $106.8 million for the nine months ended September 30, 2024, an increase of $0.3 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the nine months ended September 30, 2025 and 2024 were 24.8% and 26.0%, respectively. The increase in expenses was primarily driven by the acceleration of stock-based compensation expense for employees who are nearing or have reached retirement eligibility and higher incentive compensation, partially offset by a reduction of CD related acquisition costs, the benefits of restructuring actions, and reduced intangible amortization costs. The decrease in expenses as a percentage of revenues was driven by higher revenues.
Interest Expense, net
Interest expense for the nine months ended September 30, 2025 was $7.5 million, compared with $12.9 million for the nine months ended September 30, 2024, a decrease of $5.4 million. The decrease is due to a lower outstanding revolving credit facility balance during the nine months ended September 30, 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 9. Borrowings to our Consolidated Financial Statements.
Other Expense, net
Other expense for the nine months ended September 30, 2025 was $2.6 million, compared with expense of $2.5 million for the nine months ended September 30, 2024, a change of $0.1 million. The change is primarily due to unfavorable foreign currency exchange rate changes.
Provision for Income Taxes and Non-GAAP Provision for Income Taxes
ETR for the nine months ended September 30, 2025 and 2024 was 26.2% and 38.1%, respectively. The ETR for the nine months ended September 30, 2025 and 2024 includes discrete items totaling $0.1 million and $0.3 million of tax benefit, respectively. The discrete items impacting the tax provision for the nine months ended September 30, 2024 are primarily attributable to stock-based compensation and the deferred tax impact of a tax rate change. Absent the discrete items, the ETR for the nine months ended September 30, 2025 and 2024 was 26.5% and 39.5%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the nine months ended September 30, 2025 and 2024. The change in the ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.
Non-GAAP ETR for the nine months ended September 30, 2025 and 2024 was 13.2% and 9.1%, respectively. The non-GAAP ETR includes discrete items totaling $0.1 million of tax expense and $0.9 million of tax benefit for the nine months ended September 30, 2025 and 2024, respectively. Absent the discrete items, the non-GAAP ETR for the nine months ended September 30, 2025 and 2024 was 13.1% and 10.5%, respectively. The change in the non-GAAP ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.
Earnings from Continuing Operations
Earnings from continuing operations for the nine months ended September 30, 2025 was $25.4 million, compared with $13.0 million for the nine months ended September 30, 2024, an improvement of $12.4 million. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher operating expenses and income tax expense.
Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes
EBIT for the nine months ended September 30, 2025 was $41.9 million, compared with $33.9 million for the nine months ended September 30, 2024, an increase of $8.0 million. EBIT margin for the nine months ended September 30, 2025 was 9.7%, compared with 8.2% for the nine months ended September 30, 2024. The increase in EBIT and EBIT margin was primarily due to higher gross profit, partially offset by higher operating expenses.
Adjusted EBIT from continuing operations for the nine months ended September 30, 2025 was $83.9 million, compared with $78.5 million for the nine months ended September 30, 2024, an increase of $5.4 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 19.5%, compared with 19.1% for the nine months ended September 30, 2024. The increase in Adjusted EBIT and Adjusted EBIT margin was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses.
Loss from Discontinued Operations, net
Loss from discontinued operations for the nine months ended September 30, 2025 was $2.2 million, compared with a loss of $269.3 million for the nine months ended September 30, 2024. Loss from discontinued operations for the nine months ended September 30, 2025 was primarily driven by an unfavorable working capital adjustment and tax expense. Loss from discontinued operations for the nine months ended September 30, 2024 was primarily driven by goodwill impairment and loss on disposal of business related to the divestiture of CMM, partially offset by favorable income tax changes. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.
Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations
Diluted earnings per share from continuing operations was $0.29 for the nine months ended September 30, 2025, compared with $0.14 for the nine months ended September 30, 2024, an improvement of $0.15. As described above, the improvement is primarily due to higher gross profit, lower interest expense and reduced share count, partially offset by by higher operating expenses and income tax expense.
Non-GAAP diluted earnings per share from continuing operations was $0.75 for the nine months ended September 30, 2025 and $0.65 for the nine months ended September 30, 2024, an improvement of $0.10. As described above, the improvement is primarily due to higher non-GAAP gross profit, lower interest expense, and reduced share count, partially offset by higher non-GAAP income tax expense and non-GAAP operating expenses.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (1)
(in millions, except per share amounts)
| Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 | |
|---|---|---|---|---|
| Gross profit | $69.9 | $62.9 | $183.8 | $173.9 |
| Stock-based compensation expense | 0.3 | 0.3 | 1.1 | 1.1 |
| Impairment charges | — | — | 3.6 | — |
| Restructuring charges | 0.2 | 0.1 | 0.7 | 1.4 |
| Production transfer costs (2) | 0.6 | 1.3 | 0.9 | 2.8 |
| Acquisition-related costs (3) | — | 0.2 | — | 2.2 |
| Transition services credit (4) | (0.3) | — | (0.7) | — |
| Other (5) | — | — | 0.8 | 1.1 |
| Non-GAAP gross profit | $70.7 | $64.8 | $190.2 | $182.5 |
| Net earnings from continuing operations | $18.0 | $9.2 | $25.4 | $13.0 |
| Interest expense, net | 2.3 | 3.9 | 7.5 | 12.9 |
| Provision for income taxes | 4.3 | 3.0 | 9.0 | 8.0 |
| Earnings from continuing operations before interest and income taxes | 24.6 | 16.1 | 41.9 | 33.9 |
| Stock-based compensation expense | 5.9 | 5.8 | 22.4 | 16.8 |
| Intangibles amortization expense | 4.0 | 4.2 | 12.1 | 12.8 |
| Impairment charges | — | — | 3.6 | — |
| Restructuring charges | 0.3 | 0.2 | 3.2 | 2.9 |
| Production transfer costs (2) | 0.6 | 1.4 | 1.0 | 3.0 |
| Acquisition-related costs (3) | (0.1) | 1.3 | 0.6 | 7.5 |
| Transition services credit (4) | (0.5) | — | (1.7) | — |
| Other (5) | (0.3) | 1.0 | 0.8 | 1.6 |
| Adjusted earnings from continuing operations before interest and income taxes | $34.5 | $30.0 | $83.9 | $78.5 |
| Provision for income taxes | $4.3 | $3.0 | $9.0 | $8.0 |
| Income tax effects of non-GAAP reconciling adjustments (6) | (1.0) | (1.1) | 1.1 | (2.0) |
| Non-GAAP provision for income taxes | $3.3 | $1.9 | $10.1 | $6.0 |
| Net earnings from continuing operations | $18.0 | $9.2 | $25.4 | $13.0 |
| Non-GAAP reconciling adjustments (7) | 9.9 | 13.9 | 42.0 | 44.6 |
| Income tax effects of non-GAAP reconciling adjustments (6) | (1.0) | (1.1) | 1.1 | (2.0) |
| Non-GAAP net earnings | $28.9 | $24.2 | $66.3 | $59.6 |
| Diluted earnings per share from continuing operations | $0.21 | $0.10 | $0.29 | $0.14 |
| Earnings per share non-GAAP reconciling adjustment (6) (7) (8) | 0.12 | 0.17 | 0.46 | 0.51 |
| Non-GAAP diluted earnings per share (8) | $0.33 | $0.27 | $0.75 | $0.65 |
| Diluted average shares outstanding | 87.3 | 89.7 | 88.1 | 90.2 |
| Non-GAAP adjustment (8) (9) | 0.6 | 1.6 | 0.7 | 1.5 |
| Non-GAAP diluted average shares outstanding (8) (9) | 87.9 | 91.3 | 88.8 | 91.7 |
34
(1) In addition to the GAAP financial measures included herein, Knowles has presented certain non-GAAP financial measures that exclude certain amounts that are included in the most directly comparable GAAP measures. Knowles believes that non-GAAP measures are useful as supplements to its GAAP results of operations to evaluate certain aspects of its operations and financial performance, and its management team primarily focuses on non-GAAP items in evaluating Knowles' performance for business planning purposes. Knowles also believes that these measures assist it with comparing its performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in Knowles' opinion, do not reflect its core operating performance. Knowles believes that its presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that Knowles uses internally for purposes of assessing its core operating performance.
(2) Production transfer costs represent duplicate costs incurred to migrate manufacturing to existing facilities. These amounts are included in the corresponding Gross profit and Earnings from continuing operations before interest and income taxes for each period presented.
(3) These expenses are related to the acquisition of CD by the PD segment. These expenses include ongoing costs to facilitate integration, the amortization of fair value adjustments to inventory, and costs incurred by the Company to carry out this transaction.
(4) Transition services represent amounts charged to Syntiant in connection with post-closing transition and separation costs.
(5) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.
(6) Income tax effects of non-GAAP reconciling adjustments are calculated using the applicable tax rates in the jurisdictions of the underlying adjustments.
(7) The non-GAAP reconciling adjustments include stock-based compensation expense, intangibles amortization expense, restructuring charges, production transfer costs, acquisition-related costs, and other expenses, partially offset by a credit to transition services.
(8) In the third quarter of 2025, the Company modified its calculation method of Non-GAAP diluted average shares outstanding to exclude the potential dilution impact from performance share units ("PSUs") as these equity awards have not yet been earned. Our PSUs are market-based awards and have fluctuated based on the Company's total shareholder return performance relative to the Russell 2000 during the measurement period. The calculation methodology change in Non-GAAP diluted average shares outstanding increased Non-GAAP diluted earnings per share by $0.01 for both the three months ended September 30, 2025 and 2024, $0.02 for the nine months ended September 30, 2025, and $0.01 for the nine months ended September 30, 2024.
(9) The number of shares used in the diluted average shares outstanding calculations on a non-GAAP basis excludes the impact of stock-based compensation expense expected to be incurred in future periods and not yet recognized in the financial statements, which would otherwise be assumed to be used to repurchase shares under the GAAP treasury stock method. Non-GAAP diluted average shares outstanding also excludes the impact of certain equity awards that are not yet earned.
Segment Results of Operations for the Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024
The following is a summary of the results of operations of our two reportable segments: Precision Devices and Medtech & Specialty Audio.
See Note 15. Segment Information to the Consolidated Financial Statements for (i) a reconciliation of segment revenues to our consolidated revenues and (ii) a reconciliation of segment adjusted earnings before interest and income taxes to our consolidated earnings before income taxes and discontinued operations.
Precision Devices
(in millions)
| Three Months Ended September 30, 2025 | Percent of Revenues | 2024 | Percent of Revenues | |
|---|---|---|---|---|
| Revenues | $88.2 | $78.8 | ||
| Earnings from continuing operations before interest and income taxes | $14.3 | 16.2% | $8.4 | 10.7% |
| Stock-based compensation expense | 1.1 | 0.7 | ||
| Intangibles amortization expense | 4.0 | 4.2 | ||
| Restructuring charges | 0.3 | 0.2 | ||
| Production transfer costs (1) | 0.6 | 1.4 | ||
| Acquisition-related costs (2) | (0.1) | 1.2 | ||
| Adjusted earnings from continuing operations before interest and income taxes | $20.2 | 22.9% | $16.1 | 20.4% |
| (1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities. | ||||
| (2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration. |
Revenues
PD revenues were $88.2 million for the third quarter of 2025, compared with $78.8 million for the third quarter of 2024, an increase of $9.4 million or 11.9%. Revenues increased due to higher demand in the defense, electrification, medtech, and industrial markets, as well as higher average pricing.
Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes
PD EBIT was $14.3 million for the third quarter of 2025, compared with $8.4 million for the third quarter of 2024, an increase of $5.9 million. EBIT margin for the third quarter of 2025 was 16.2%, compared to 10.7% for the third quarter of 2024. The increases were due to higher gross profit primarily driven by higher shipping volumes, product cost reductions and increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.
PD Adjusted EBIT was $20.2 million for the third quarter of 2025, compared with $16.1 million for the third quarter of 2024, an increase of $4.1 million. Adjusted EBIT margin for the third quarter of 2025 was 22.9%, compared with 20.4% for the third quarter of 2024. The increases were due to higher non-GAAP gross profit. The non-GAAP gross profit increase was driven by higher shipping volumes, product cost reductions and increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.
MedTech & Specialty Audio
(in millions)
| Three Months Ended September 30, 2025 | Percent of Revenues | 2024 | Percent of Revenues | |
|---|---|---|---|---|
| Revenues | $64.7 | $63.7 | ||
| Earnings from continuing operations before interest and income taxes | $25.0 | 38.6% | $25.0 | 39.2% |
| Stock-based compensation expense | 1.2 | 1.1 | ||
| Adjusted earnings from continuing operations before interest and income taxes | $26.2 | 40.5% | $26.1 | 41.0% |
Revenues
MSA revenues were $64.7 million for the third quarter of 2025, compared with $63.7 million for the third quarter of 2024, an increase of $1.0 million or 1.6%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and higher shipping volumes into the specialty audio market, partially offset by lower shipping volumes into the hearing health market.
Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes
MSA EBIT was $25.0 million for both the third quarter of 2025 and the third quarter of 2024. EBIT margin for the third quarter of 2025 was 38.6%, compared with 39.2% for the third quarter of 2024. The EBIT margin decrease is primarily due to unfavorable product mix and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by product cost reductions.
MSA Adjusted EBIT was $26.2 million for the third quarter of 2025, compared with $26.1 million for the third quarter of 2024, an increase of $0.1 million. Adjusted EBIT margin for the third quarter of 2025 was 40.5%, compared to 41.0% for the third quarter of 2024. The increase in adjusted EBIT was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses. Higher non-GAAP gross profit was driven by product cost reductions and higher shipping volumes, partially offset by unfavorable product mix. The decrease in Adjusted EBIT margin was primarily due to unfavorable product mix and the impact of higher shipping volumes of our lower margin metal can products to Syntiant.
Segment Results of Operations for the Nine Months Ended September 30, 2025 compared with the Nine Months Ended September 30, 2024
Precision Devices
(in millions)
| Nine Months Ended September 30, 2025 | Percent of Revenues | 2024 | Percent of Revenues | |
|---|---|---|---|---|
| Revenues | $239.2 | $227.2 | ||
| Earnings before interest and income taxes | $25.7 | 10.7% | $10.5 | 4.6% |
| Stock-based compensation expense | 3.7 | 1.5 | ||
| Intangibles amortization expense | 12.1 | 12.8 | ||
| Restructuring charges | 1.7 | 2.9 | ||
| Production transfer costs (1) | 1.0 | 3.0 | ||
| Acquisition-related costs (2) | 0.6 | 6.5 | ||
| Other | — | 0.5 | ||
| Adjusted earnings before interest and income taxes | $44.8 | 18.7% | $37.7 | 16.6% |
| (1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities. | ||||
| (2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration and the amortization of fair value adjustments to inventory. |
Revenues
PD revenues were $239.2 million for the nine months ended September 30, 2025, compared with $227.2 million for the nine months ended September 30, 2024, an increase of $12.0 million or 5.3%. Revenues increased due to higher demand from the medtech, electrification, and defense markets, as well as higher average pricing, partially offset by lower demand from the industrial market.
Earnings and Adjusted Earnings Before Interest and Income Taxes
PD EBIT was $25.7 million for the nine months ended September 30, 2025, compared with $10.5 million for the nine months ended September 30, 2024, an increase of $15.2 million. EBIT margin for the nine months ended September 30, 2025 was 10.7%, compared to 4.6% for nine months ended September 30, 2024. The increases were primarily due to higher gross profit and lower operating expenses. The gross profit increase was primarily driven by product cost reductions, higher shipping volumes, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, lower CD related acquisition and production transfer costs, higher average pricing, lower precious metal costs, and reduced restructuring charges, partially offset by lower than expected yields in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments. The decrease in operating expenses was primarily driven by a reduction of CD acquisition related costs, the benefits of restructuring actions, and lower intangible amortization costs, partially offset by higher stock-based compensation.
PD Adjusted EBIT was $44.8 million for the nine months ended September 30, 2025, compared with $37.7 million for the nine months ended September 30, 2024, an increase of $7.1 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 18.7%, compared with 16.6% for the nine months ended September 30, 2024. The increases were primarily due to higher non-GAAP gross profit and lower non-GAAP operating expenses. The non-GAAP gross profit increase was primarily driven by product cost reductions, higher shipping volumes, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, higher average pricing, and lower precious metal costs, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments.
MedTech & Specialty Audio
(in millions)
| Nine Months Ended September 30, 2025 | Percent of Revenues | 2024 | Percent of Revenues | |
|---|---|---|---|---|
| Revenues | $191.8 | $183.8 | ||
| Earnings before interest and income taxes | $65.3 | 34.0% | $71.9 | 39.1% |
| Stock-based compensation expense | 4.4 | 3.1 | ||
| Impairment charges | 3.6 | — | ||
| Restructuring charges | 0.3 | — | ||
| Adjusted earnings before interest and income taxes | $73.6 | 38.4% | $75.0 | 40.8% |
Revenues
MSA revenues were $191.8 million for the nine months ended September 30, 2025, compared with $183.8 million for the nine months ended September 30, 2024, an increase of $8.0 million or 4.4%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio market, partially offset by lower average pricing on mature products and lower shipping volumes into the hearing health market.
Earnings and Adjusted Earnings Before Interest and Income Taxes
MSA EBIT was $65.3 million for the nine months ended September 30, 2025, compared with $71.9 million for the nine months ended September 30, 2024, a decrease of $6.6 million or 9.2%. EBIT margin for the nine months ended September 30, 2025 was 34.0%, compared with 39.1% for the nine months ended September 30, 2024. The decreases were primarily due to lower gross profit and higher operating expenses. The gross profit decrease was primarily due to higher factory costs, lower average pricing on mature products, impairment charges recorded in the second quarter of 2025, unfavorable product mix, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes and product cost reductions. The increase in operating expenses was primarily driven by higher stock-based compensation and legal costs.
MSA Adjusted EBIT was $73.6 million for the nine months ended September 30, 2025, compared with $75.0 million for the nine months ended September 30, 2024, a decrease of $1.4 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 38.4%, compared to 40.8% for the nine months ended September 30, 2024. The decreases were primarily due to higher non-GAAP operating expenses and lower non-GAAP gross profit. The increase in non-GAAP operating expenses was primarily driven by higher legal costs. The decrease in non-GAAP gross profit was primarily due to higher factory costs, lower average pricing on mature products, unfavorable product mix, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes and product cost reductions.
Liquidity and Capital Resources
Historically, we have generated and expect to continue to generate positive cash flow from operations. Our ability to fund our operations and capital needs will depend on our ongoing ability to generate cash from operations and access to capital markets. We believe that our future cash flow from operations and access to capital markets will provide adequate resources to fund our working capital needs, capital expenditures, strategic investments, and share repurchases. We have secured a revolving line of credit in the United States from a syndicate of commercial banks to provide additional liquidity. Furthermore, if we were to require additional cash above and beyond our cash on the balance sheet, the free cash flow generated by the business, and availability under our revolving credit facility, we would most likely seek to raise long-term financing through the U.S. debt or bank markets.
Due to the global nature of our operations, a portion of our cash is generated and typically held outside the United States. Our cash and cash equivalents totaled $92.5 million and $130.1 million at September 30, 2025 and December 31, 2024, respectively. Of these amounts, cash held by our non-U.S. operations totaled $21.2 million and $92.4 million as of September 30, 2025 and December 31, 2024, respectively. To the extent we repatriate these funds to the U.S., we may be required to pay U.S. state income taxes and applicable foreign withholding taxes on those amounts during the period when such repatriation occurs. Management will continue to reassess our need to repatriate the earnings of our foreign subsidiaries.
On December 27, 2024, we completed the sale of the CMM segment to Syntiant for approximately $141.9 million in total consideration, consisting of $63.6 million in cash ($58.0 million net of cash sold), Syntiant Series D-2 preferred stock with a fair value of $77.2 million, and $1.1 million for estimated purchase price adjustments. The purchase price adjustment amount is still being negotiated and is subject to change. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements. We will also share in certain separation costs pursuant to a credit for up to $13.5 million, which the buyer may apply to specified separation costs post-closing. As the balance of the separation credit is now below the $6.5 million contractual threshold, costs will be shared equally by the Company and Syntiant. For additional information, refer to Note 1. Basis of Presentation.
On February 24, 2020, we announced that our Board of Directors had authorized a share repurchase program of up to $100.0 million of our common stock. On April 28, 2022, we announced that our Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value, for a total of $400.0 million of aggregate value. At September 30, 2025, we have $139.0 million remaining that may yet be repurchased under our share repurchase program. The timing and amount of any shares repurchased will be determined by us based on our evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. We are not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock. During the nine months ended September 30, 2025 and 2024, the Company repurchased 3,120,574 and 1,686,253 shares of common stock, respectively, for a total of $55.0 million and $29.5 million, respectively.
Cash flows from operating, investing, and financing activities as reflected in our Consolidated Statements of Cash Flows and are presented on a consolidated basis, including discontinued operations. Cash flows are summarized in the following table:
(in millions)
| Net cash flows provided by (used in): | Nine Months Ended September 30, 2025 | 2024 |
|---|---|---|
| Operating activities | $66.8 | $95.0 |
| Investing activities | (16.3) | (3.1) |
| Financing activities | (88.6) | (87.2) |
| Effect of exchange rate changes on cash and cash equivalents | 0.5 | 0.6 |
| Net (decrease) increase in cash and cash equivalents | $(37.6) | $5.3 |
40
Operating Activities
Cash provided by operating activities adjusts net earnings for certain non-cash items, including impairment charges, depreciation expense, amortization of intangible assets, stock-based compensation, changes in deferred income taxes, and the effects of changes in operating assets and liabilities. The decrease in cash provided by operating activities in 2025 is primarily due to $31.2 million of payments in 2025 to settle supplier obligations and separation costs related to CMM and the absence of $22.1 million of cash generated by CMM in 2024. This decrease was partially offset by customer prepayments of $19.8 million, higher earnings from continuing operations, and lower interest payments in 2025.
Investing Activities
The cash used in investing activities during 2025 was driven by capital expenditures, which is primarily driven by capacity expansion related to our specialty film product line and cost savings. The cash used in investing activities during 2024 was primarily driven by capital expenditures, partially offset by proceeds from the sale of intellectual property.
In 2025, we expect capital expenditures to be in the range of 4% to 6% of revenues.
Financing Activities
Cash used in financing activities during 2025 was primarily related to $55.0 million of repurchases of common stock, $30.0 million of payments on the revolving credit facility, and $7.1 million of tax payments related to net share settlement of equity awards, partially offset by proceeds of $3.9 million from the exercise of options. Cash used in financing activities during 2024 was primarily related to $29.5 million of repurchases of common stock, $52.0 million net payments on the revolving credit facility, and $6.4 million for payment of taxes related to net share settlement of equity awards, partially offset by proceeds of $2.1 million from the exercise of options.
Adjusted Free Cash Flow
In addition to measuring cash flow generation based on the operating, investing, and financing classifications included in the Consolidated Statement of Cash Flows (including discontinued operations), Knowles also measures adjusted free cash flow and adjusted free cash flow as a percentage of revenues. Adjusted free cash flow is defined as non-GAAP net cash attributable to continuing operations less non-GAAP capital expenditures attributable to continuing operations. Non-GAAP net cash attributable to continuing operations is defined as net cash provided by operating activities less amounts generated or utilized by discontinued operations. Non-GAAP capital expenditures attributable to continuing operations is defined as capital expenditures less amounts attributable to discontinued operations. Knowles believes these measures are helpful in measuring its cash generated from its continuing operations that is available to repay debt, fund acquisitions, and repurchase Knowles common stock. Adjusted free cash flow and adjusted free cash flow as a percentage of revenues are not presented in accordance with GAAP and may not be comparable to similarly titled measures used by other companies in our industry. As such, adjusted free cash flow and adjusted free cash flow as a percentage of revenues should not be considered in isolation from, or as an alternative to, any other liquidity measures determined in accordance with GAAP.
The following table reconciles our adjusted free cash flow to cash flow provided by operating activities:
(in millions)
| Nine Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| Net cash provided by operating activities | $66.8 | $95.0 |
| Amounts utilized in (provided by) in discontinued operations | 31.2 | (22.1) |
| Non-GAAP net cash attributable to continuing operations | 98.0 | 72.9 |
| Capital expenditures | (16.8) | (10.3) |
| Amounts attributable to discontinued operations | — | 0.9 |
| Non-GAAP capital expenditures attributable to continuing operations | (16.8) | (9.4) |
| Non-GAAP net cash attributable to continuing operations | 98.0 | 72.9 |
| Non-GAAP capital expenditures attributable to continuing operations | (16.8) | (9.4) |
| Adjusted free cash flow | $81.2 | $63.5 |
| Adjusted free cash flow as a % of revenues | 18.8% | 15.5% |
In 2025 we generated adjusted free cash flow of $81.2 million compared to adjusted free cash flow of $63.5 million in 2024. The increase in adjusted free cash flow in 2025 was primarily due to customer prepayments of $19.8 million, higher earnings from continuing operations, and lower interest payments, partially offset by higher capital expenditures and an increase in working capital.
Contingent Obligations
We are involved in various legal proceedings, claims, and investigations arising in the ordinary course of business. Legal contingencies are discussed in Note 14. Commitments and Contingent Liabilities to our Consolidated Financial Statements.
Critical Accounting Estimates
This discussion and analysis of results of operations and financial condition is based on our Consolidated Financial Statements, which have been prepared in conformity with U.S. GAAP. The preparation of these financial statements requires the use of estimates and assumptions related to the reporting of assets, liabilities, revenues, expenses, and related disclosures. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements. Estimates are revised periodically. Actual results could differ from these estimates.
The information concerning our critical accounting estimates can be found under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 13, 2025. There are no material changes in our previously reported critical accounting estimates.
Recent Accounting Standards
The issuance of recent accounting standards, as included in Note 2. Recent Accounting Standards to our Consolidated Financial Statements, is not expected to have a significant impact on our revenue, earnings, or liquidity.
Market risk
As filed, 437 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
During the nine months ended September 30, 2025, there were no material changes to the information on market risk exposure disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024. For a discussion of our exposure to market risk as of December 31, 2024, refer to Item 7A, Quantitative and Qualitative Disclosures about Market Risk, contained in our Annual Report on Form 10-K for the year ended December 31, 2024.
Controls and procedures
As filed, 2,963 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management has evaluated, under the supervision and with the participation of our chief executive officer ("CEO") and chief financial officer ("CFO"), the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on that evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There has been no change in our internal control over financial reporting that occurred during the third quarter of 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including the CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, will be detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by intentionally falsified documentation, by collusion of two or more individuals within Knowles or third parties, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
Risk factors
As filed, 183 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $152.9m | us-gaap:Revenues |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $431.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $82.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $242.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $69.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $183.8m | us-gaap:GrossProfit |
| Research and development | 3 months2025-07-01 to 2025-09-30 | $10.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $29.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-07-01 to 2025-09-30 | $34.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-01-01 to 2025-09-30 | $107.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | $25.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | $44.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-07-01 to 2025-09-30 | $4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | $9.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | $17.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | $23.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | $0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | $0.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | $0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | $0.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 87,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 88,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | $66.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-01-01 to 2025-09-30 | $16.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2025-01-01 to 2025-09-30 | $55.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-09-30 | $92.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $334.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $1.09bn | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $176.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2025-09-30 | $104.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-09-30 | $72.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-09-30 | $751.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001587523-25-000079. Last ingested by Listed: Nov 11, 2026, 02:23 ET. Listed shows no prices and gives no investment advice.